Abstract
This Letter describes the development and SAR of a novel series of GlyT1 inhibitors derived from a scaffold hopping approach, in lieu of an HTS campaign, which provided intellectual property position. Members within this new [3.3.0]-based series, e.g. I, displayed excellent GlyT1 potency, selectivity, free fraction, and modest CNS penetration. Moreover, enantioselective GlyT1 inhibition was obsd., within this novel series and a no. of other piperidine bioisosteric cores.
| Original language | English |
|---|---|
| Pages (from-to) | 1062-1066 |
| Number of pages | 5 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 24 |
| Issue number | 4 |
| Early online date | 13 Jan 2014 |
| DOIs | |
| Publication status | Published - 15 Feb 2014 |
Fingerprint
Dive into the research topics of 'Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres'. Together they form a unique fingerprint.Research output
- 8 Citations
- 1 Comment/debate
-
Corrigendum to “Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres” [Bioorg. Med. Chem. Lett. 24 (2014) 1062–1066]
Sheffler, D. J., Nedelcovych, M. T., Williams, R., Turner, S. C., Duerk, B. B., Robbins, M. R., Jadhav, S. B., Niswender, C. M., Jones, C. K., Jeffrey Conn, P., Nathan Daniels, R. & Lindsley, C. W., 24 Mar 2017, In: Bioorganic and Medicinal Chemistry Letters. 27, 9, p. 2079 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver